Insulins
14 drugs in this class, prescribed by 233,733 Medicare Part D providers.
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$4.94B
Total Cost
6,882,935
Claims
14
Drugs
$717
Avg Cost/Claim
Key Insights
- Most expensive per prescription: Omnipod Dash Pods (Gen 4) at $1,286/claim
- Most prescribed: Lantus Solostar with 3,118,259 claims
- This class represents 1.8% of total Medicare Part D spending
All Insulins Drugs
| Drug | Cost | Claims |
|---|---|---|
| Insulin Glargine,hum.Rec.Anlog | $1.94B | 3,118,259 |
| Insulin Aspart | $831.6M | 958,823 |
| Insulin Lispro | $623.9M | 854,813 |
| Insulin Degludec | $567.8M | 597,178 |
| Insulin Detemir | $376.5M | 548,216 |
| Insulin Regular, Human | $119.4M | 143,017 |
| Insulin Glargine/Lixisenatide | $92.5M | 82,886 |
| Insulin Aspart Prot/Insuln Asp | $88.8M | 79,814 |
| Insulin Nph Hum/Reg Insulin Hm | $82.3M | 177,501 |
| Insulin Lispro Protamin/Lispro | $62.8M | 60,873 |
| Insulin Pump Cart,automated,bt | $57.6M | 48,024 |
| Insulin Nph Human Isophane | $44.9M | 172,714 |
| Insulin Aspart (Niacinamide) | $27.0M | 24,598 |
| Insulin Pump Cart,cont Inf,bt | $20.9M | 16,219 |